Triggered by concerns over an increased risk of cardiovascular side effects, Merck announced on 30 September the withdrawal of rofecoxib (Vioxx), its leading drug for the management of rheumatoid ...

Merck last week agreed to pay nearly $5 billion to settle most of the claims generated by its nowwithdrawn painkiller Vioxx, said Matthew Herper and Robert Langreth in Forbes.com. Plaintiffs ...

Cardiovasc Rev Rep. 2004;25(6):288-290. The recent sudden withdrawal of Vioxx (rofecoxib; Merck & Co., Whitehouse Station, NJ) from the market owing to safety concerns has created considerable ...

The Week is part of Future US Inc, an international media group and leading digital publisher. Visit our corporate site.